• Profile
Close

SGLT2 inhibitors for type 2 diabetes mellitus in adults: An overview of forty-six systematic reviews

Diabetes, Obesity and Metabolism Jun 24, 2021

Augusto GA, Cassola N, Dualib PM, et al. - Researchers sought to summarize the evidence from systematic reviews (SRs) of randomized controlled trials (RCTs) assessing the effectiveness and safety of SGLT2 inhibitors (SGLT2i) vs placebo or active comparators for type 2 diabetes mellitus. Between 2014 and 2021, six databases were searched. They involved forty-six SRs, comprising 175 RCTs and 136,096 candidates. "Possible benefit" was noted in relation to major cardiovascular events, all-cause mortality, and nonalcoholic fatty liver disease. SGLT2i displayed "clear evidence of no effect or equivalence" in relation to stroke and fractures. "Clear evidence of harm" was seen in relation to genital infections and ketoacidosis. SGLT2i have been shown to improve renal and cardiovascular outcomes (except for stroke), HbA1c, and weight.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay